\-\ Texto\\:\\ \ \(0\)\
\-\ right\\ knee\\ findings\\:\ \(0\)\
\-\ minimal\\ warmth\\ noted\\.\\ \ \(0\)\
\-\ no\\ erythema\\.\ \(1\)\
\-\ no\\ subcutaneous\\ nodules\\.\\ \ \(0\)\
\-\ minimally\\ tender\\ to\\ palpation\\ along\\ joint\\ line\\.\\ \ \(0\)\
\-\ full\\ range\\ with\\ both\\ active\\ and\\ passive\\ motion\\.\\ \\ \ \(0\)\
\-\ negative\\ anterior\\/posterior\\ drawer\\ sign\\.\ \(0\)\
\-\ the\\ issue\\ of\\ ongoing\\ urate\\ deposition\\ should\\ be\\ addressed\\ with\\ uricosuric\\ medication\\.\\ \\ probenecid\\ \\(benemid\\)\\ is\\ the\\ most\\ frequently\\ used\\ medication\\.\\ \\ probenecid\\ works\\ at\\ the\\ level\\ of\\ the\\ proximal\\ tubule\\ by\\ blocking\\ reabsorption\\ of\\ filtered\\ uric\\ acid\\.\\ this\\ action\\ is\\ inhibited\\ by\\ low\\-dose\\ salicylates\\;\\ this\\ fact\\ accounts\\ for\\ a\\ significant\\ number\\ of\\ \\"treatment\\ failures\\.\\"\\ allopurinol\\ \\(zyloprim\\)\\ can\\ also\\ be\\ used\\ and\\ is\\ currently\\ the\\ only\\ readily\\ available\\ inhibitor\\ of\\ uric\\ acid\\ synthesis\\.\ \(0\)\
\-\ tophi\\ should\\ not\\ be\\ surgically\\ removed\\ unless\\ they\\ are\\ in\\ a\\ critical\\ location\\ or\\ drain\\ chronically\\.\ \(0\)\
\-\ there\\ is\\ no\\ evidence\\ of\\ bone\\ marrow\\ abnormality\\.\\ \\ a\\ small\\ joint\ \(0\)\
\-\ effusion\\ is\\ present\\.\\ \\ a\\ large\\ nodular\\ mass\\ is\\ seen\\ adjacent\\ to\\ the\\ lateral\\ superior\\ patella\\ with\\ isointense\\ signal\\ on\\ t1\\ and\\ heterogeneous\\ signal\\ on\\ t2\\ measuring\\ approximately\\ 5\\.2\\ x\\ 1\\.8\\ x\\ 6\\ cm\\.\\ smaller\\ similar\\ masses\\ are\\ present\\ at\\ the\\ femoropopliteal\\ insertion\\ site\\,\\ within\\ the\\ femoral\\ notch\\ and\\ at\\ the\\ base\\ of\\ the\\ hoffa\\'s\\ fat\\ pad\\ just\\ anterior\\ to\\ the\\ anteromedial\\ tibia\\.\ \(0\)\
\-\ \\ \ \(1082074\)\
\-\ the\\ pcl\\ appears\\ thickened\\ but\\ intact\\.\\ \\ the\\ acl\\,\\ menisci\\,\\ and\\ collateral\ \(0\)\
\-\ ligament\\ complexes\\ are\\ unremarkable\\.\\ \\ full\\ thickness\\ fissuring\\ is\\ present\\ in\\ the\\ medial\\ trochlea\\ cartilage\\.\ \(0\)\
\-\ tophaceous\\ gout\ \(5\)\
\-\ \\>\\>\\ gout\ \(0\)\
\-\ \\>\\>\\ pigmented\\ villonodular\\ synovitis\ \(0\)\
\-\ \\>\\>\\ pseudogout\ \(0\)\
\-\ \\>\\>\\ tumor\ \(0\)\
\-\ \\>\\>\\ uric\\ acid\\ nephropathy\ \(0\)\
\-\ \\>\\>\\ rheumatoid\\ arthritis\ \(0\)\
\-\ \\>\\>\\ sarcoidosis\ \(0\)\
\-\ \\>\\>\\ amyloidosis\ \(0\)\
\-\ 40\\ year\\ old\\ male\\ with\\ history\\ of\\ gout\\ presents\\ with\\ chronic\\ knee\\ pain\\ for\\ 5\\ months\\.\ \(1\)\
\-\ mri\\ is\\ not\\ used\\ routinely\\ in\\ the\\ evaluation\\ of\\ gout\\.\\ however\\,\\ when\\ gouty\\ tophi\\ present\\ as\\ soft\\-tissue\\ masses\\ in\\ the\\ absence\\ of\\ articular\\ disease\\,\\ the\\ tophi\\ may\\ be\\ confused\\ with\\ a\\ neoplastic\\ process\\.\\ in\\ this\\ instance\\,\\ mri\\ evaluation\\ is\\ necessary\\.\\ tophaceous\\ deposition\\ should\\ be\\ considered\\ in\\ the\\ differential\\ diagnosis\\ when\\ a\\ mass\\ displays\\ heterogeneous\\ low\\ to\\ intermediate\\ signal\\ intensity\\ on\\ t1\\ and\\ t2\\ weighting\\ and\\ a\\ variable\\ enhancement\\ pattern\\,\\ especially\\ if\\ multiple\\ foci\\ exist\\ around\\ the\\ knee\\ joint\\ such\\ as\\ in\\ this\\ individual\\.\\ remarkably\\,\\ the\\ adjacent\\ bone\\ to\\ these\\ particular\\ tophi\\ did\\ not\\ show\\ typical\\ erosive\\ changes\\,\\ which\\ is\\ an\\ unexpected\\ finding\\ in\\ a\\ patient\\ with\\ a\\ chronic\\ history\\ of\\ gout\\ and\\ knee\\ pain\\.\\ as\\ such\\,\\ needle\\ biopsy\\ was\\ necessary\\ to\\ rule\\ out\\ a\\ neoplastic\\ and\\ chronic\\ infectious\\ etiology\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ \\>\\:\\ 0\\.10418963356581888\ \(0\)\
\-\ tophi\\:\\ 0\\.06815801892519824\ \(0\)\
\-\ gout\\:\\ 0\\.05493310473889162\ \(0\)\
\-\ uric\\:\\ 0\\.04355925532691627\ \(0\)\
\-\ probenecid\\:\\ 0\\.03725858368535116\ \(0\)\
\-\ acid\\:\\ 0\\.034464605051808574\ \(0\)\
\-\ tophaceous\\:\\ 0\\.030359146085459993\ \(0\)\
\-\ knee\\:\\ 0\\.028426520390461254\ \(0\)\
\-\ used\\:\\ 0\\.022556313006522673\ \(0\)\
\-\ deposition\\:\\ 0\\.021892051174917194\ \(0\)\
\-\ uricosuric\\:\\ 0\\.020219078954051603\ \(0\)\
\-\ benemid\\:\\ 0\\.020219078954051603\ \(0\)\
\-\ filtered\\:\\ 0\\.020219078954051603\ \(0\)\
\-\ zyloprim\\:\\ 0\\.020219078954051603\ \(0\)\
\-\ fissuring\\:\\ 0\\.020219078954051603\ \(0\)\
\-\ neoplastic\\:\\ 0\\.020059023704019182\ \(0\)\
\-\ medication\\:\\ 0\\.019746141823163525\ \(0\)\
\-\ joint\\:\\ 0\\.01901442147964735\ \(0\)\
\-\ should\\:\\ 0\\.01874455418730826\ \(0\)\
\-\ tubule\\:\\ 0\\.01862929184267558\ \(0\)\
\-\ inhibited\\:\\ 0\\.01862929184267558\ \(0\)\
\-\ salicylates\\:\\ 0\\.01862929184267558\ \(0\)\
\-\ femoropopliteal\\:\\ 0\\.01862929184267558\ \(0\)\
\-\ weighting\\:\\ 0\\.01862929184267558\ \(0\)\
\-\ present\\:\\ 0\\.01770650232964845\ \(0\)\
\-\ necessary\\:\\ 0\\.01736275459896359\ \(0\)\
\-\ urate\\:\\ 0\\.01703950473129956\ \(0\)\
\-\ low\\-dose\\:\\ 0\\.01703950473129956\ \(0\)\
\-\ remarkably\\:\\ 0\\.01703950473129956\ \(0\)\
\-\ full\\:\\ 0\\.016933735984235043\ \(0\)\
\-\ chronic\\:\\ 0\\.016561855272295874\ \(0\)\
\-\ reabsorption\\:\\ 0\\.016527707595257794\ \(0\)\
\-\ failures\\:\\ 0\\.016527707595257794\ \(0\)\
\-\ synthesis\\:\\ 0\\.016527707595257794\ \(0\)\
\-\ anterior\\/posterior\\:\\ 0\\.016109538887014777\ \(0\)\
\-\ blocking\\:\\ 0\\.016109538887014777\ \(0\)\
\-\ trochlea\\:\\ 0\\.016109538887014777\ \(0\)\
\-\ allopurinol\\:\\ 0\\.01575598228190639\ \(0\)\
\-\ signal\\:\\ 0\\.015502805024812698\ \(0\)\
\-\ hoffa\\:\\ 0\\.015449717619923538\ \(0\)\
\-\ complexes\\:\\ 0\\.015449717619923538\ \(0\)\
\-\ pseudogout\\:\\ 0\\.015449717619923538\ \(0\)\
\-\ instance\\:\\ 0\\.015449717619923538\ \(0\)\
\-\ be\\:\\ 0\\.0151118890291735\ \(0\)\
\-\ addressed\\:\\ 0\\.014937920483881772\ \(0\)\
\-\ works\\:\\ 0\\.014937920483881772\ \(0\)\
\-\ chronically\\:\\ 0\\.014937920483881772\ \(0\)\
\-\ action\\:\\ 0\\.01471931915405534\ \(0\)\
\-\ 5\\.2\\:\\ 0\\.01471931915405534\ \(0\)\
\-\ routinely\\:\\ 0\\.01471931915405534\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.014413739251353237\ \(0\)\
\-\ nephropathy\\:\\ 0\\.014336167583726975\ \(0\)\
\-\ gouty\\:\\ 0\\.014336167583726975\ \(0\)\
\-\ inhibitor\\:\\ 0\\.014007954639596991\ \(0\)\
\-\ issue\\:\\ 0\\.013589785931353977\ \(0\)\
\-\ menisci\\:\\ 0\\.013589785931353977\ \(0\)\
\-\ villonodular\\:\\ 0\\.013589785931353977\ \(0\)\
\-\ exist\\:\\ 0\\.0134657785431194\ \(0\)\
\-\ displays\\:\\ 0\\.01334813337250575\ \(0\)\
\-\ masses\\:\\ 0\\.01325042384401875\ \(0\)\
\-\ readily\\:\\ 0\\.013236229326245585\ \(0\)\
\-\ drawer\\:\\ 0\\.013027578458801259\ \(0\)\
\-\ anteromedial\\:\\ 0\\.013027578458801259\ \(0\)\
\-\ unexpected\\:\\ 0\\.013027578458801259\ \(0\)\
\-\ x\\:\\ 0\\.012931496951135216\ \(0\)\
\-\ is\\:\\ 0\\.012896577485888204\ \(0\)\
\-\ pcl\\:\\ 0\\.012836336236463986\ \(0\)\
\-\ warmth\\:\\ 0\\.012659820087069196\ \(0\)\
\-\ 1\\.8\\:\\ 0\\.012576408059154345\ \(0\)\
\-\ notch\\:\\ 0\\.01249592338068813\ \(0\)\
\-\ pigmented\\:\\ 0\\.01249592338068813\ \(0\)\
\-\ individual\\:\\ 0\\.01249592338068813\ \(0\)\
\-\ t1\\:\\ 0\\.012424291450569926\ \(0\)\
\-\ adjacent\\:\\ 0\\.012393744239148016\ \(0\)\
\-\ ongoing\\:\\ 0\\.01234296151257191\ \(0\)\
\-\ accounts\\:\\ 0\\.01234296151257191\ \(0\)\
\-\ amyloidosis\\:\\ 0\\.012270143397171494\ \(0\)\
\-\ such\\:\\ 0\\.012253820136884645\ \(0\)\
\-\ critical\\:\\ 0\\.012199566198394537\ \(0\)\
\-\ synovitis\\:\\ 0\\.01206461092311258\ \(0\)\
\-\ pad\\:\\ 0\\.01193715713606026\ \(0\)\
\-\ soft\\-tissue\\:\\ 0\\.011816414628066174\ \(0\)\
\-\ passive\\:\\ 0\\.011758346261129728\ \(0\)\
\-\ acl\\:\\ 0\\.011758346261129728\ \(0\)\
\-\ erosive\\:\\ 0\\.011646442214869563\ \(0\)\
\-\ confused\\:\\ 0\\.011592473184112238\ \(0\)\
\-\ patella\\:\\ 0\\.01148820168393619\ \(0\)\
\-\ evaluation\\:\\ 0\\.011386416494618384\ \(0\)\
\-\ intermediate\\:\\ 0\\.011292885609761173\ \(0\)\
\-\ when\\:\\ 0\\.011226290080807366\ \(0\)\
\-\ t2\\:\\ 0\\.01109444389335024\ \(0\)\
\-\ drain\\:\\ 0\\.010790469173837585\ \(0\)\
\-\ unless\\:\\ 0\\.010609779087018515\ \(0\)\
\-\ insertion\\:\\ 0\\.010609779087018515\ \(0\)\
\-\ articular\\:\\ 0\\.010507825503140457\ \(0\)\
\-\ particular\\:\\ 0\\.010507825503140457\ \(0\)\
\-\ variable\\:\\ 0\\.010442290245241246\ \(0\)\
\-\ fact\\:\\ 0\\.010316583280803185\ \(0\)\
\-\ collateral\\:\\ 0\\.010256222481910125\ \(0\)\
\-\ subcutaneous\\:\\ 0\\.010197409567659351\ \(0\)\
\-\ minimally\\:\\ 0\\.010197409567659351\ \(0\)\
\-\ cartilage\\:\\ 0\\.010197409567659351\ \(0\)\
\-\ thickness\\:\\ 0\\.010111924717206984\ \(0\)\
\-\ needle\\:\\ 0\\.009976170425027327\ \(0\)\
\-\ surgically\\:\\ 0\\.009924041408794401\ \(0\)\
\-\ number\\:\\ 0\\.009774407184325592\ \(0\)\
\-\ bone\\:\\ 0\\.009740526061742524\ \(0\)\
\-\ erythema\\:\\ 0\\.00963394015395697\ \(0\)\
\-\ isointense\\:\\ 0\\.00963394015395697\ \(0\)\
\-\ smaller\\:\\ 0\\.00950158162730411\ \(0\)\
\-\ rheumatoid\\:\\ 0\\.009257786538658186\ \(0\)\
\-\ a\\:\\ 0\\.009096325729784433\ \(0\)\
\-\ mri\\:\\ 0\\.009005852545479908\ \(0\)\
\-\ tibia\\:\\ 0\\.009002681870974185\ \(0\)\
\-\ ligament\\:\\ 0\\.009002681870974185\ \(0\)\
\-\ as\\:\\ 0\\.00889388192128987\ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.008852503133865224\ \(0\)\
\-\ removed\\:\\ 0\\.008836407783730713\ \(0\)\
\-\ this\\:\\ 0\\.00881777259921223\ \(0\)\
\-\ thickened\\:\\ 0\\.008788788537289363\ \(0\)\
\-\ marrow\\:\\ 0\\.008622184905087593\ \(0\)\
\-\ not\\:\\ 0\\.008496458750517905\ \(0\)\
\-\ frequently\\:\\ 0\\.00849433632020632\ \(0\)\
\-\ infectious\\:\\ 0\\.008426272631797795\ \(0\)\
\-\ foci\\:\\ 0\\.008412898961360197\ \(0\)\
\-\ arthritis\\:\\ 0\\.008373239564318772\ \(0\)\
\-\ etiology\\:\\ 0\\.008295920625460258\ \(0\)\
\-\ site\\:\\ 0\\.008283283800205741\ \(0\)\
\-\ 40\\:\\ 0\\.008245785777266453\ \(0\)\
\-\ nodular\\:\\ 0\\.008221123410807137\ \(0\)\
\-\ just\\:\\ 0\\.00818462007294957\ \(0\)\
\-\ rule\\:\\ 0\\.00818462007294957\ \(0\)\
\-\ around\\:\\ 0\\.008160603330134672\ \(0\)\
\-\ absence\\:\\ 0\\.008148688612526635\ \(0\)\
\-\ nodules\\:\\ 0\\.008125043269272367\ \(0\)\
\-\ especially\\:\\ 0\\.008066974902335922\ \(0\)\
\-\ line\\:\\ 0\\.00805553558694363\ \(0\)\
\-\ are\\:\\ 0\\.0080151871963046\ \(0\)\
\-\ at\\:\\ 0\\.007966260225905733\ \(0\)\
\-\ tender\\:\\ 0\\.007955070856075755\ \(0\)\
\-\ considered\\:\\ 0\\.00791179451592809\ \(0\)\
\-\ range\\:\\ 0\\.00789045875294113\ \(0\)\
\-\ motion\\:\\ 0\\.007879864840426694\ \(0\)\
\-\ typical\\:\\ 0\\.007858822693004582\ \(0\)\
\-\ measuring\\:\\ 0\\.007837971840478774\ \(0\)\
\-\ currently\\:\\ 0\\.007766451364706554\ \(0\)\
\-\ in\\:\\ 0\\.007732059268628531\ \(0\)\
\-\ minimal\\:\\ 0\\.007716697179818344\ \(0\)\
\-\ similar\\:\\ 0\\.007687354630598368\ \(0\)\
\-\ base\\:\\ 0\\.007677656611998548\ \(0\)\
\-\ process\\:\\ 0\\.007546021754208061\ \(0\)\
\-\ pattern\\:\\ 0\\.007491840227227702\ \(0\)\
\-\ active\\:\\ 0\\.007482933117075414\ \(0\)\
\-\ femoral\\:\\ 0\\.007456417469366525\ \(0\)\
\-\ effusion\\:\\ 0\\.007447646605975691\ \(0\)\
\-\ appears\\:\\ 0\\.007295249588984516\ \(0\)\
\-\ abnormality\\:\\ 0\\.0072306374858498905\ \(0\)\
\-\ intact\\:\\ 0\\.007199001425913341\ \(0\)\
\-\ intensity\\:\\ 0\\.0070841070559158285\ \(0\)\
\-\ did\\:\\ 0\\.007076648259158083\ \(0\)\
\-\ they\\:\\ 0\\.0070618030424020786\ \(0\)\
\-\ biopsy\\:\\ 0\\.00695342486613936\ \(0\)\
\-\ location\\:\\ 0\\.006836485520421773\ \(0\)\
\-\ sign\\:\\ 0\\.006790014912302915\ \(0\)\
\-\ available\\:\\ 0\\.006588805157889443\ \(0\)\
\-\ palpation\\:\\ 0\\.0065411446796973674\ \(0\)\
\-\ by\\:\\ 0\\.006526930748829701\ \(0\)\
\-\ unremarkable\\:\\ 0\\.006488684446518488\ \(0\)\
\-\ along\\:\\ 0\\.0064771877909599\ \(0\)\
\-\ out\\:\\ 0\\.0064771877909599\ \(0\)\
\-\ the\\:\\ 0\\.006341710307505771\ \(0\)\
\-\ finding\\:\\ 0\\.006316654828069912\ \(0\)\
\-\ medial\\:\\ 0\\.00626903558162856\ \(0\)\
\-\ superior\\:\\ 0\\.0062585864611334665\ \(0\)\
\-\ differential\\:\\ 0\\.006222384929708554\ \(0\)\
\-\ \\,\\:\\ 0\\.006208946456818518\ \(0\)\
\-\ approximately\\:\\ 0\\.006063802354485282\ \(0\)\
\-\ show\\:\\ 0\\.006016412693788133\ \(0\)\
\-\ fat\\:\\ 0\\.005960808080003746\ \(0\)\
\-\ no\\:\\ 0\\.0059204872754848765\ \(0\)\
\-\ only\\:\\ 0\\.005893146005699394\ \(0\)\
\-\ proximal\\:\\ 0\\.0058842733525390255\ \(0\)\
\-\ to\\:\\ 0\\.005877084061142013\ \(0\)\
\-\ negative\\:\\ 0\\.005853486608657969\ \(0\)\
\-\ 6\\:\\ 0\\.005853486608657969\ \(0\)\
\-\ 5\\:\\ 0\\.005734312895514137\ \(0\)\
\-\ level\\:\\ 0\\.005648828045061771\ \(0\)\
\-\ changes\\:\\ 0\\.005617082514300598\ \(0\)\
\-\ however\\:\\ 0\\.005457266182562088\ \(0\)\
\-\ mass\\:\\ 0\\.005451655995172315\ \(0\)\
\-\ low\\:\\ 0\\.005449926726757797\ \(0\)\
\-\ history\\:\\ 0\\.0054138281546196486\ \(0\)\
\-\ months\\:\\ 0\\.005353076363968044\ \(0\)\
\-\ if\\:\\ 0\\.005318218884817971\ \(0\)\
\-\ significant\\:\\ 0\\.005270291630858311\ \(0\)\
\-\ cm\\:\\ 0\\.005256780086736207\ \(0\)\
\-\ enhancement\\:\\ 0\\.0052534146011996245\ \(0\)\
\-\ evidence\\:\\ 0\\.005138629778364399\ \(0\)\
\-\ these\\:\\ 0\\.005100561220086789\ \(0\)\
\-\ anterior\\:\\ 0\\.005047689962758573\ \(0\)\
\-\ both\\:\\ 0\\.005005045850197527\ \(0\)\
\-\ on\\:\\ 0\\.00498090146123001\ \(0\)\
\-\ \\`\\`\\:\\ 0\\.00481682348080692\ \(0\)\
\-\ pain\\:\\ 0\\.004787193429040068\ \(0\)\
\-\ \\'\\'\\:\\ 0\\.00472419610546386\ \(0\)\
\-\ noted\\:\\ 0\\.0046454614414050315\ \(0\)\
\-\ \\;\\:\\ 0\\.0046454614414050315\ \(0\)\
\-\ tumor\\:\\ 0\\.0045693401413092\ \(0\)\
\-\ most\\:\\ 0\\.004524851242495588\ \(0\)\
\-\ small\\:\\ 0\\.00451508092747963\ \(0\)\
\-\ diagnosis\\:\\ 0\\.00450050305224867\ \(0\)\
\-\ can\\:\\ 0\\.004445464111167591\ \(0\)\
\-\ \\'s\\:\\ 0\\.004321207840291388\ \(0\)\
\-\ may\\:\\ 0\\.004298918277289275\ \(0\)\
\-\ large\\:\\ 0\\.004285647779429082\ \(0\)\
\-\ lateral\\:\\ 0\\.0042354771688636475\ \(0\)\
\-\ but\\:\\ 0\\.004180053442737472\ \(0\)\
\-\ findings\\:\\ 0\\.004171644348142109\ \(0\)\
\-\ multiple\\:\\ 0\\.004127995420824012\ \(0\)\
\-\ presents\\:\\ 0\\.004003771319972307\ \(0\)\
\-\ treatment\\:\\ 0\\.003967011375231392\ \(0\)\
\-\ seen\\:\\ 0\\.00387299911712773\ \(0\)\
\-\ also\\:\\ 0\\.0038638064075003473\ \(0\)\
\-\ within\\:\\ 0\\.0037388335054726646\ \(0\)\
\-\ and\\:\\ 0\\.0037157822284173535\ \(0\)\
\-\ which\\:\\ 0\\.0036585885028498828\ \(0\)\
\-\ male\\:\\ 0\\.00354404939882448\ \(0\)\
\-\ for\\:\\ 0\\.0033445327919390602\ \(0\)\
\-\ \\(\\:\\ 0\\.0033135859002011952\ \(0\)\
\-\ \\)\\:\\ 0\\.003273108679418831\ \(0\)\
\-\ disease\\:\\ 0\\.0032035264706782207\ \(0\)\
\-\ of\\:\\ 0\\.0029393160751786072\ \(0\)\
\-\ there\\:\\ 0\\.0029167787992316254\ \(0\)\
\-\ an\\:\\ 0\\.002710240514414518\ \(0\)\
\-\ \\:\\:\\ 0\\.0025923734311712504\ \(0\)\
\-\ or\\:\\ 0\\.0022970705251461184\ \(0\)\
\-\ was\\:\\ 0\\.002266691564710291\ \(0\)\
\-\ year\\:\\ 0\\.0021929019937452173\ \(0\)\
\-\ \\.\\:\\ 0\\.0021169448131445026\ \(0\)\
\-\ right\\:\\ 0\\.00206796263557435\ \(0\)\
\-\ old\\:\\ 0\\.0020067307267482904\ \(0\)\
\-\ patient\\:\\ 0\\.001964660392010064\ \(0\)\
\-\ with\\:\\ 0\\.0018785074142872206\ \(0\)\
